The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genmab (I)
Stock and Other Ownership Interests - Genmab (I)
Consulting or Advisory Role - Bayer; Genmab; Roche
Research Funding - Karyopharm Therapeutics; Puma Biotechnology
 
Employment - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Leadership - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Stock and Other Ownership Interests - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Travel, Accommodations, Expenses - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Molecular predictors of response to selinexor in recurrent glioblastoma (GBM).
 
Christopher James Walker
Employment - Karyopharm Therapeutics
Consulting or Advisory Role - Karyopharm Therapeutics
Travel, Accommodations, Expenses - Karyopharm Therapeutics
 
Yao Shen
No Relationships to Disclose
 
Morten Mau-Sørensen
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; deciphera; Deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Martin J. Van Den Bent
Consulting or Advisory Role - Abbvie; Agios; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; carthera; Celgene; Daiichi Sankyo; Genenta Science; Nerviano Medical Sciences
Research Funding - Abbvie (Inst)
 
Scott Randall Plotkin
Stock and Other Ownership Interests - NF2 Therapeutics; NFlection Therapeutics
Consulting or Advisory Role - AstraZeneca; NFlection Therapeutics
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - NFlection Therapeutics
(OPTIONAL) Uncompensated Relationships - Pfizer (Inst)
 
Anna Maria Elisabeth Walenkamp
Consulting or Advisory Role - Ipsen (Inst); Karyopharm Therapeutics (Inst); Polyphor (Inst)
Research Funding - Ipsen (Inst); Novartis (Inst)
 
Adam Green
No Relationships to Disclose
 
Andrea Califano
Stock and Other Ownership Interests - DarwinHealth; regeneron; Teva
Honoraria - Shanghai Cell Therapy Group; Xiamen Enchang Group
Consulting or Advisory Role - Abbvie; DarwinHealth
Patents, Royalties, Other Intellectual Property - The technology developed by my lab, including ARACNe, VIPER, OncoTreat/OncoTarget, MINDy, and DEMAND were licensed exclusively to DarwinHealth, Inc. Columbia receives royalties from these licenses and both my lab and I share a portion of these roylaties
Travel, Accommodations, Expenses - Abbvie; DarwinHealth
 
Hua Chang
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Travel, Accommodations, Expenses - Karyopharm Therapeutics
 
Leah Henegar
Employment - Karyopharm Therapeutics
Travel, Accommodations, Expenses - Regeneron
 
Sharon Shacham
No Relationships to Disclose
 
Mariano J Alvarez
Patents, Royalties, Other Intellectual Property - DarwinHealth
Other Relationship - DarwinHealth
 
Yosef Landesman
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Travel, Accommodations, Expenses - Karyopharm Therapeutics
 
Andrew B. Lassman
Honoraria - Abbott Molecular; WebMD
Consulting or Advisory Role - Abbvie; Agios; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Northwest Biotherapeutics; Orbus Therapeutics; QED Therapeutics; SapVax
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Amgen (Inst); Bayer (Inst); BeiGene (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Keryx (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Oncoceutics